Accuronix Therapeutics

Accuronix Therapeutics is a leader in discovering and developing a new class of drugs that work by selectively targeting the s-2 (sigma-2) receptor on cancer cells to deliver cytotoxic payloads. The Accuronix team has established an innovative platform and a lead drug candidate based on advances in characterizing the molecular-targeted drug conjugate (MTDC) approach to cancer therapy. The s-2 receptors are highly expressed on the surface of rapidly proliferating cancer cells. They internalize upon ligand binding, allowing the delivery of therapeutic agents to intracellular targets. The result is a chemotherapeutic with increased effectiveness and reduction in toxicity risk. In January 2016, Accuronix licensed our s-2-based technology from Washington University in St. Louis and assembled a team of experienced biotech scientists and executives, the technology originators, and key executional partners. Accuronix's s-2 platform enables the discovery of selective molecularly targeted drug conjugates for a variety of therapeutic cargoes to treat a range of cancers. We are working to advance the development of the lead candidate, ACXT-3102 for pancreatic adenocarcinoma and other rare tumor types; and to progress next-generation MTDCs into development for other oncology indications.